Sappi delivers solid performance for first financial quarter 2023

Commenting on the group’s results, Sappi Chief Executive Officer Steve Binnie said: “I am pleased with another strong performance from the Group which was well above pre-Covid levels and the best ever first quarter results. EBITDA of US$290 million was 21% above the prior year and in line with guidance provided in the previous quarter. The positive results were underpinned by year-on-year pricing gains for paper products which offset cost inflation, lower sales volumes and delivered an EBITDA margin of 17.5%.”

The lower profits relative to the record levels in the prior quarter were reflective of the slowing global economy, which led to a softening in demand for our products, driven by the volatile and uncertain macroeconomic context including ongoing geopolitical turmoil, rampant inflation, rising interest rates and an underperforming Chinese economy as well as rapid downstream inventory accumulation in all our major product categories.

Looking forward, Binnie stated: “Factoring in the protracted macroeconomic uncertainty, and coming off three quarters of outperformance, we anticipate a return to a normalised level of earnings in FY2023. The second quarter will likely be the most challenging with a recovery in earnings expected later in the financial year. EBITDA for the second quarter of FY2023 is expected to be below that of the first quarter.”

Financial summary for the quarter
• EBITDA excluding special items US$290 million (Q1 FY22 US$240 million)
• Net debt US$1,241 million (Q1 FY22 US$1,917 million)
• Profit for the period US$190 million (Q1 FY22 US$123 million)
• EPS excluding special items 30 US Cents (Q1 FY22 20 US Cents)
https://www.sappi.com/news-and-events-listing?field_regions_tid=All&field_news_article_type_value=All&field_article_date_value%5Bvalue%5D%5Byear%5D=&items_per_page=10

Related Posts

UPM Biomedicals and CELLINK form collaboration for groundbreaking 3D bioprinting developments

UPM Biomedicals is excited to announce its collaboration with bioconvergence company CELLINK. The partnership brings together UPM’s expertise for producing non-animal derived, nanocellulose biomaterials with CELLINK’s years of experience in method development for 3D bioprinting, offering new groundbreaking solutions to this growing life sciences market. Advances in 3D printing in the past decade have been outstanding, and the technology is becoming more widely used for various cutting-edge applications. 3D bioprinting is already important in areas such as cancer research, where tumour models can be printed to test their response to different treatments. More recently scientists have been exploring the use of this technology in a clinical setting, with the possibility of printing tissues or organs that can then be transplanted into patients. Using non-animal derived raw materials, such as UPM’s nanofibrillar cellulose, for bio-ink formulations makes transplants into humans much more effective, reducing the possibility of an immune response or rejection.

Monadnock Paper Announces Rajan Iyer as New Vice President of Research & Development and Technical Services

Monadnock Paper Mills, Inc. is pleased to announce the appointment of Dr. Rajan Iyer as its new Vice President of Research & Development and Technical Services. Dr. Iyer will oversee the company’s new product development efforts, guiding Monadnock’s portfolio development of award-winning and sustainably-advantaged fine printing, packaging, and technical papers. He replaces Paul Ciccone who has announced his retirement. Paul (Mr. Ciccone), a 41-year Monadnock veteran, will remain with the company for an undetermined period of time to ensure a smooth transition.

Conciliator submits settlement proposals for UPM Specialty Papers and UPM Raflatac

Conciliator Leo Suomaa has submitted proposals for UPM Specialty Papers and UPM Raflatac in the collective labour negotiations with the Paperworkers’ Union. The conciliator has asked the parties to state their position on the proposals by 14 April 2022 at 10:00 EEST, which is also the deadline for the settlement proposal for UPM Pulp, given earlier by the conciliator. In the meanwhile, conciliation will continue between the Union and UPM Biofuels. The conciliation for UPM Communication Papers was interrupted last weekend, and no further meetings have been agreed. "I am pleased that the negotiations have reached a point where conciliation settlements are presented. I hope agreements will be reached soon, and we get to start the mills", says Riitta Savonlahti, Executive Vice President, Human Resources at UPM.
Back To Top
×Close search
Search